AI-assisted skin sensitization assay to predict allergenic agents and chemicals
Regulatory accepted CompanySenzaGen, Lund, Sweden
GARD®skin is an in vitro test method for identifying and evaluating active ingredients and chemicals that trigger allergic reactions in the skin. For this purpose, the test substances are brought into contact with a human dendritic cell line (SenzaCell™), which simulates a critical part of the immune system. A machine learning platform then analyses the gene expression pattern of the exposed sample and compares it with existing data sets that include 196 biomarkers associated with known skin allergens. The GARD®skin Assay distinguishes between sensitizing and non-sensitizing substances with over 90% accuracy. The method can be used in a variety of different test procedures. The GARD®skin technology also enables the analysis of “difficult to test” samples, such as complex mixtures, indirectly acting haptens, lipophilic compounds, metals, metal salts, solid materials and surfactants. In summary, SenzaGen's skin sensitization assay proves to be a valuable and innovative method for evaluating skin sensitizers and for identifying new relevant biomarkers. The integrated AI-based learning platform generates meaningful results for researchers within a period of 4–8 weeks, significantly reducing the duration of previous test procedures and studies for safety testing of active ingredients and chemicals to be tested. Validated and regulatory approved under OECD test no. 442E.
GARD®skin. OECD TG 442E: in vitro skin sensitization
info@senzagen.com
Added on: 11-15-2023
[1] https://senzagen.com/gardskin/
